2seventy bio (TSVT) Price & Analysis

Compare

276 Followers

TSVT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.29 - $5.30

Previous CloseN/A

Volume53.84K

Average Volume (3M)N/A

Market Cap

$266.15M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.42

Next Earnings

Aug 06, 2025

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.01

Shares Outstanding53,229,790

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$5.00

Price Target Upside0.00%

Rating ConsensusHold

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Acquisition PremiumThe acquisition of 2Seventy Bio by Bristol-Myers Squibb implies an 80% premium to the previous closing price, boosting investor confidence.

Cash Position2Seventy Bio ended the quarter with $192 million in cash, providing a solid financial base and extending its cash runway beyond 2027.

Bears Say

Market UncertaintyMarket uncertainty persists with the expected launch of a third BCMA CAR-T by competitors, posing a threat to Abecma's market position.

Revenue Challenges2Seventy's top-line revenue fell short of expectations, highlighting challenges in capturing anticipated profits from Abecma.

2seventy bio News

2Seventy Bio Reports Strong Q1 2025 Earnings

2Seventy Bio, Inc. ( ($TSVT) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

TSVT

2seventy bio Completes Merger, Delists from Nasdaq

2seventy bio ( ($TSVT) ) just unveiled an update. On May 13, 2025, 2seventy bio completed a merger...

3M ago

TSVT

2seventy bio Reports 2024 Earnings Amid BMS Merger

2Seventy Bio, Inc. ( ($TSVT) ) has released its Q4 earnings. Here is a breakdown of the information...

4M ago

TSVT

2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year

Reports Q4 revenue $2.9M, consensus $13.03M. “2024 was a pivotal year for 2seventy as we made significant changes...

4M ago

TSVT

Is TSVT a Buy, Before Earnings?

2Seventy Bio, Inc. (TSVT) is scheduled to report 4th quarter earnings on 03/25/2025. Regarding Q4 estimates, Wall Street...

4M ago

TSVT

2seventy bio Delays Yearly Report Filing

2seventy bio ( ($TSVT) ) has released a notification of late filing. 2seventy bio, Inc. has announced a...

5M ago

TSVT

2seventy Bio price target lowered to $5 from $6 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an...

5M ago

BMY

TSVT

Hold Rating Amidst Favorable Acquisition Terms and Competitive Pressures for 2seventy bio

Vikram Purohit, an analyst from Morgan Stanley, maintained the Hold rating on 2seventy bio (TSVT – Research Report)....

5M ago

TSVT

Spotify upgraded, Freshpet downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

5M ago

BMY

Morning Movers: 2seventy Bio skyrockets following acquisition by Bristol Myers

Stock index futures are edging higher this morning, attempting a modest rebound following the largest one-day decline of...

5M ago

AAL

2seventy Bio downgraded to Market Perform from Outperform at Leerink

Leerink downgraded 2seventy Bio (TSVT) (TVST) to Market Perform from Outperform with a price target of $5, down...

5M ago

BMY

TSVT

2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cash

2seventy Bio (TSVT) announced a definitive merger agreement under which Bristol Myers Squibb (BMY) will acquire all of...

5M ago

BMY

TSVT

2seventy Bio reports preliminary FY25 Abecma revenue $242M

Reports approximately $184M of cash, cash equivalents and marketable securities as of December 31; Net cash burn of...

6M ago

TSVT

Regeneron pays $1M milestone payment to Medigene

Medigene announced a $1M milestone payment from Regeneron (REGN) was triggered. Regeneron purchased the MAGE-A4-TCR program as part...

8M ago

REGN

TSVT

TSVT FAQ

What was 2Seventy Bio, Inc.’s price range in the past 12 months?

2Seventy Bio, Inc. lowest stock price was $2.29 and its highest was $5.30 in the past 12 months.

What is 2Seventy Bio, Inc.’s market cap?

2Seventy Bio, Inc.’s market cap is $266.15M.

When is 2Seventy Bio, Inc.’s upcoming earnings report date?

2Seventy Bio, Inc.’s upcoming earnings report date is Aug 06, 2025 which is in 6 days.

How were 2Seventy Bio, Inc.’s earnings last quarter?

Currently, no data Available

Is 2Seventy Bio, Inc. overvalued?

According to Wall Street analysts 2Seventy Bio, Inc.’s price is currently same. Get more investment ideas with TipRanks Premium

Does 2Seventy Bio, Inc. pay dividends?

2Seventy Bio, Inc. does not currently pay dividends.

What is 2Seventy Bio, Inc.’s EPS estimate?

2Seventy Bio, Inc.’s EPS estimate is -0.15.

How many shares outstanding does 2Seventy Bio, Inc. have?

2Seventy Bio, Inc. has 53,229,790 shares outstanding.

What happened to 2Seventy Bio, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of 2Seventy Bio, Inc.?

Currently, no hedge funds are holding shares in TSVT

2seventy bio Stock Smart Score

Underperform

Fundamentals

Return on Equity

-1.94%

Trailing 12-Months

Asset Growth

-6.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

2Seventy Bio, Inc.

2seventy bio (TSVT) is a biotechnology company focused on the development and commercialization of innovative cell therapies for the treatment of cancer. Operating in the biopharmaceutical sector, 2seventy bio is dedicated to advancing its pipeline of autologous and allogeneic therapies to improve the lives of patients with serious and life-threatening oncologic diseases.

2seventy bio (TSVT) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

TSVT Earnings Data >

TSVT Stock 12 Month Forecast

Average Price Target

$5.00

▲(0.00%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","2.25":"$2.25","3.5":"$3.5","4.75":"$4.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.25,3.5,4.75,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Aug<br/>2024","9":"Nov<br/>2024","12":"Mar<br/>2025","25":"Mar<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.64,2.8215384615384616,3.0030769230769234,3.184615384615385,3.3661538461538463,3.5476923076923077,3.729230769230769,3.910769230769231,4.092307692307692,4.273846153846154,4.455384615384616,4.636923076923077,4.818461538461539,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.64,2.8215384615384616,3.0030769230769234,3.184615384615385,3.3661538461538463,3.5476923076923077,3.729230769230769,3.910769230769231,4.092307692307692,4.273846153846154,4.455384615384616,4.636923076923077,4.818461538461539,{"y":5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.64,2.8215384615384616,3.0030769230769234,3.184615384615385,3.3661538461538463,3.5476923076923077,3.729230769230769,3.910769230769231,4.092307692307692,4.273846153846154,4.455384615384616,4.636923076923077,4.818461538461539,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.19,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.64,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.79,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.6,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.23,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.28,"date":1722470400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.87,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Similar Stocks

ARCT

Arcturus Therapeutics

―

RNAC

Cartesian Therapeutics

―

TSHA

Taysha Gene Therapies

―

AVIR